Lori L Jennings
Overview
Explore the profile of Lori L Jennings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bortnick A, Austin T, Hamerton E, Gudmundsdottir V, Emilsson V, Jennings L, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e036336.
PMID: 40008515
Background: Calcific aortic valve disease (CAVD), and ensuing severe aortic stenosis (AS), is the foremost valvular disorder of aging, yet preventive therapies are lacking. A better understanding of the molecular...
2.
Bankier S, Gudmundsdottir V, Jonmundsson T, Bjarnadottir H, Loureiro J, Wang L, et al.
medRxiv
. 2025 Feb;
PMID: 39974043
Variations in blood protein levels have been associated with a broad spectrum of complex diseases, including atherosclerotic cardiovascular disease (ACVD). These associations highlight the intricate interplay between local (e.g., cardiovascular)...
3.
Frick E, Emilsson V, Jonmundsson T, Steindorsdottir A, Johnson E, Puerta R, et al.
Nat Aging
. 2024 Sep;
4(10):1509.
PMID: 39285016
No abstract available.
4.
Wang R, Gomez Salazar M, Prunonosa Cervera I, Coutts A, French K, Pinto M, et al.
Nat Commun
. 2024 Aug;
15(1):7483.
PMID: 39209825
Enhancing thermogenic brown adipose tissue (BAT) function is a promising therapeutic strategy for metabolic disease. However, predominantly thermoneutral modern human living conditions deactivate BAT. We demonstrate that selective adipocyte deficiency...
5.
Frick E, Emilsson V, Jonmundsson T, Steindorsdottir A, Johnson E, Puerta R, et al.
Nat Aging
. 2024 Aug;
4(10):1446-1464.
PMID: 39169269
A deeper understanding of the molecular processes underlying late-onset Alzheimer's disease (LOAD) could aid in biomarker and drug target discovery. Using high-throughput serum proteomics in the prospective population-based Age, Gene/Environment...
6.
Dammer E, Shantaraman A, Ping L, Duong D, Gerasimov E, Ravindran S, et al.
Sci Transl Med
. 2024 Jun;
16(753):eadn3504.
PMID: 38924431
Alzheimer's disease (AD) is currently defined by the aggregation of amyloid-β (Aβ) and tau proteins in the brain. Although biofluid biomarkers are available to measure Aβ and tau pathology, few...
7.
Liu X, Axelsson G, Newman A, Psaty B, Boudreau R, Wu C, et al.
Aging Cell
. 2024 Mar;
23(6):e14136.
PMID: 38440820
The identification of protein targets that exhibit anti-aging clinical potential could inform interventions to lengthen the human health span. Most previous proteomics research has been focused on chronological age instead...
8.
Axelsson G, Jonmundsson T, Woo Y, Frick E, Aspelund T, Loureiro J, et al.
Respir Res
. 2024 Jan;
25(1):44.
PMID: 38238732
Background: A decline in forced expiratory volume (FEV1) is a hallmark of respiratory diseases that are an important cause of morbidity among the elderly. While some data exist on biomarkers...
9.
Frick E, Emilsson V, Jonmundsson T, Steindorsdottir A, Johnson E, Puerta R, et al.
medRxiv
. 2023 Nov;
PMID: 37986771
The current demand for early intervention, prevention, and treatment of late onset Alzheimer's disease (LOAD) warrants deeper understanding of the underlying molecular processes which could contribute to biomarker and drug...
10.
Dammer E, Shantaraman A, Ping L, Duong D, Gerasimov E, Ravindran S, et al.
medRxiv
. 2023 Nov;
PMID: 37961720
Alzheimer's disease (AD) is currently defined at the research level by the aggregation of amyloid-β (Aβ) and tau proteins in brain. While biofluid biomarkers are available to measure Aβ and...